✦ LIBER ✦

Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia

✍ Scribed by Anders Wahlin

Book ID: 112962866
Publisher: Springer US
Year: 1989
Tongue: English
Weight: 463 KB
Volume: 6
Category: Article
ISSN: 1357-0560
DOI: 10.1007/bf02985191

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Population pharmacokinetics of cytarabin

Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia

✍ Mikkel Krogh-Madsen; Brendan Bender; Morten Krogh Jensen; Ove Juul Nielsen; Lena 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 346 KB

Therapy-related myelodysplastic syndrome

✍ Cecilia Arana-Yi; AnneMarie W. Block; Sheila N. Sait; Laurie A. Ford; Maurice Ba 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 331 KB

Treatment of acute leukemia with idarubi

Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule

✍ LloydE. Damon; LauraJ. Johnston; CurtA. Ries; HopeS. Rugo; Delvyn Case; Kenneth 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 199 KB

Combined action of PSC 833 (Valspodar),

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

✍ Visani, G; Milligan, D; Leoni, F; Chang, J; Kelsey, S; Marcus, R; Powles, R; Sch 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 130 KB

Salvage therapy combining high-dose cyta

Salvage therapy combining high-dose cytarabine with amsacrine in refractory acute myeloid leukemia (AML): analysis of prognostic factors

✍ E. Tavernier; Q.H. Le; X. Thomas 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 342 KB

Phase I study of VP-16 (etoposide) and a

Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia

✍ Letendre, Louis ;Hinemann, Vicky ;Hoagland, H. Clark ;Kovach, John S. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB

Fourteen patients with refractory acute nonlymphocytic leukemia were entered into a doseseeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days. There were three complete responses lasting 2 months, 3 months, and 10 months and two transient partial rem